Skip to content

Daniel H. Grossman

5 papers in the library · 25 citations · publishing 2025-2026

Papers

Sort Most recent Most cited

Psilocybin in the Treatment of Cocaine Use Disorder

JAMA Network Open May 7, 2026 Peter S. Hendricks, Sara N Lappan, Richard C. Shelton et al. 4 citations

Importance: Cocaine use disorder is a serious public health problem and no medications have been proven effective for its treatment. Objective: To evaluate psilocybin in the treatment of cocaine use disorder. It was hypothesized that psilocybin, compared with placebo, would yield a higher percentage of cocaine abstinent days, a greater likelihood of complete abstinence from cocaine, and a...

How do psychedelics impact people with a history of non-affective psychosis? A qualitative study.

Front Psychiatry December 9, 2025 Haley Maria Dourron, Heith Copes, Daniel H. Grossman et al. 3 citations

Background: People with a history of psychotic disorders are excluded from contemporary trials of psychedelic-assisted therapy. Although survey studies have explored the impact of naturalistic psychedelic use on people with a history of psychotic disorders, a qualitative study has yet to examine the subjective effects of psychedelic use in this population during both the acute effects and...

Naturalistic Psychedelic Use and Psychotic Symptoms: A Cross-Sectional Study of Individuals with a Personal or Family History of Psychotic or Bipolar Disorders.

Psychedelic medicine (New Rochelle, N.Y.) June 1, 2025 Haley Maria Dourron, Melissa Bradley, Otto Simonsson et al. 7 citations

Prior research examining the associations between psychedelic use and general psychotic symptoms has yielded mixed findings. However, no studies have investigated the relationships between psychedelic use and specific psychotic symptoms, and whether these relationships might differ among those with liability to psychosis, namely those with a history of psychotic or bipolar disorders. Using...

A systematic review of income and education reporting in psychedelic clinical trials

Nature Mental Health May 1, 2025 Daniel H. Grossman, Kevin R. Madden, Nicky J. Mehtani et al. 10 citations

Socioeconomic status (SES) substantially influences mental health outcomes and treatment access, yet its reporting in psychedelic-assisted therapy trials remains underexplored. Here we systematically reviewed 98 articles (49 primary trials and 49 secondary analyses) published between 2006 and 2024 examining classic psychedelics and MDMA for mental health conditions. Only 12% of primary trials...

Rural-urban divide in risk perception of LSD: Implications for psychedelic-assisted therapy.

The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association 2025 Melissa Bradley, Daniel H. Grossman, Otto Simonsson et al. 1 citation

Recent legislative initiatives in the United States have focused on the medical and legal status of psychedelics, prompting interest in understanding public perceptions of their risks. This study investigates rural-urban differences in the perception of LSD and cannabis risks using national survey data. Data from the National Survey of Drug Use and Health (NSDUH) between 2015 and 2021 were...